Zentalis Pharmaceuticals Presents Four Azenosertib Studies at AACR-NCI-EORTC Conference
核心洞察
Zentalis Pharmaceuticals announced four azenosertib abstracts accepted for poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
The presentations focus on Phase 1 results and Cyclin E1 (搜索) biomarker findings that support the company's biomarker-driven strategy for treating platinum-resistant ovarian cancer (搜索) patients.
Azenosertib targets approximately 50% of platinum-resistant ovarian cancer (搜索) patients who are Cyclin E1 (搜索)-positive, representing an underserved patient population with significant unmet medical need.
Zentalis Pharmaceuticals announced that four abstracts featuring its investigational WEE1 (搜索) inhibitor azenosertib have been accepted for poster presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 22-26, 2025 at the Hynes Convention Center in Boston, Massachusetts.
The presentations underscore the company's biomarker-driven approach targeting Cyclin E1 (搜索)-positive platinum-resistant ovarian cancer (搜索) (PROC) patients, a population representing approximately 50% of PROC cases. "The Phase 1 results and Cyclin E1 biomarker findings accepted for presentation at AACR-NCI-EORTC reinforce our biomarker-driven strategy for azenosertib in Cyclin E1-positive platinum-resistant ovarian cancer patients, an underserved patient population representing approximately 50% of PROC patients," said Dr. Ingmar Bruns, Chief Medical Officer of Zentalis.
Phase 1 Study Results and Biomarker Strategy
The lead presentation will feature results from the Phase 1 dose escalation and dose expansion study of azenosertib in patients with advanced solid tumors (搜索) (NCT04158336). Dr. Funda Meric-Bernstam from The University of Texas MD Anderson Cancer Center will present these findings on Friday, October 24, 2025.
A second presentation will outline the rationale for using azenosertib in early-line treatment of Cyclin E1 (搜索)-positive high-grade serous ovarian cancer (搜索), delivered by Dr. Mona Abed, Associate Director of Translational Biology at Zentalis. This presentation suggests potential expansion opportunities beyond the current platinum-resistant setting.
DENALI Trial Progress and Combination Studies
The conference will also feature updates on the ongoing DENALI study (GOG-3066, NCT05128825), a multi-part Phase 2 clinical trial evaluating azenosertib in platinum-resistant ovarian cancer (搜索) patients. Part 2 of the study specifically enrolls PROC patients with Cyclin E1 (搜索) protein overexpression based on Zentalis' proprietary immunohistochemistry cutoff.
The DENALI trial's Part 2 includes two components: Part 2a evaluates two dosing regimens (300mg 5:2 and 400mg 5:2), while Part 2b is designed to complete enrollment at the selected dose. The overall Part 2 study is designed for potential accelerated approval, pending study outcomes and discussions with the U.S. Food and Drug Administration.
A fourth presentation will detail a Phase 1 combination study (NCT06364410) investigating azenosertib with trastuzumab deruxtecan (DS-8201a) in HER2 (搜索)-expressing or amplified gastric/gastroesophageal junction cancer (搜索) and other solid tumors (搜索) with HER2 expression.
Mechanism of Action and Clinical Rationale
Azenosertib functions as a novel, selective, and orally bioavailable inhibitor of WEE1 (搜索), which acts as a master regulator of the G1-S and G2-M cell cycle checkpoints through negative regulation of both CDK1 (搜索) and CDK2 (搜索). By inhibiting WEE1, azenosertib enables cell cycle progression despite high levels of DNA damage, resulting in DNA damage accumulation that leads to mitotic catastrophe and cancer cell death.
In clinical trials to date, azenosertib has demonstrated tolerability and anti-tumor activity as a single agent across multiple tumor types. The company describes the compound as a potentially first-in-class and best-in-class WEE1 (搜索) inhibitor with broad franchise potential.
Dr. Bruns noted that beyond the core focus on platinum-resistant ovarian cancer (搜索), "our presentations also highlight the potential of azenosertib as a combination therapy and in earlier lines of ovarian cancer (搜索), suggesting expansion opportunities with our WEE1 (搜索) inhibition approach."